Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate

Experimental Neurology

Volumn 188, Issue 1, 2004, Pages 128-138

  Silverdale, M A ^a,b   Nicholson, S L ^a   Ravenscroft, P ^a,c   Crossman, A R ^a,c   Millan, M J ^d   Brotchie, J M ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

^c Williams House   (United Kingdom)

^d INSTITUT DE RECHERCHES SERVIER   (France)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Basal ganglia; D3; Dopamine; Dyskinesia; MPTP; Parkinson's; Primate

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; LEVODOPA; ROPINIROLE; S 33084; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DYSKINESIA; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; MARMOSET; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BENZOPYRANS; BRAIN; CALLITHRIX; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; INDOLES; LEVODOPA; PARKINSONIAN DISORDERS; PYRROLES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 2942553041     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.03.022     Document Type: Article

References (89)

1. Accili D., Fishburn C.S., Drago J., et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U. S. A. 93:1996;1945-1949
2. Albin R.L., Frey K.A. Initial agonist treatment of Parkinson disease: a critique. Neurology. 60:2003;390-394
3. Audinot V., Newman-Tancredi A., Gobert A., et al. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103, 691 and U 99194. J. Pharmacol. Exp. Ther. 287:1998;187-197
4. Aziz T.Z., Peggs D., Sambrook M.A., et al. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov. Disord. 6:1991;288-292
5. Bedard P.J., Di Paolo T., Falardeau P., et al. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res. 379:1986;294-299
6. Bergman H., Wichmann T., DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 249:1990;1436-1438
7. Betarbet R., Turner R., Chockkan V., et al. Dopaminergic neurons intrinsic to the primate striatum. J. Neurosci. 17:1997;6761-6768
8. Bezard E., Crossman A.R., Gross C.E., et al. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J. 15:2001;1092-1094
9. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 9:2003;762-767
10. Bibbiani F., Oh J.D., Chase T.N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology. 57:2001;1829-1834
11. Blanchet P.J., Konitsiotis S., Chase T.N. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 283:1997;794-799
12. Blanchet P.J., Konitsiotis S., Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 13:1998;798-802
13. Bordet R., Ridray S., Carboni S., et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3363-3367
14. Bordet R., Ridray S., Schwartz J.C., et al. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine- lesioned rats. Eur. J. Neurosci. 12:2000;2117-2123
15. Boulay D., Depoortere R., Rostene W., et al. Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology. 38:1999;555-565
16. Bouthenet M.L., Souil E., Martres M.P., et al. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 564:1991;203-219
17. Brocco M., Jackson M., Jenner P., et al. Actions of the novel naphtoxazine D3/D2 receptor agonist, S32504, in models predictive of antiparkinsonian properties. Abstr.-Soc. Neurosci. 27:2001;200-208
18. Brotchie J.M., Fox S.H. Quantitative assessment of dyskinesias in subhuman primates. Mov. Disord. 14(Suppl. 1):1999;40-47
19. Calon F., Goulet M., Blanchet P.J., Martel J.C., Piercey M.F., Bedard P.J., Di Paolo T. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res. 680:1995;43-52
20. Chio C.L., Lajiness M.E., Huff R.M. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. 45:1994;51-60
21. Clifford J.J., Waddington J.L. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach. Psychopharmacology (Berl.). 136:1998;284-290
22. Coldwell M.C., Boyfield I., Brown T., et al. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2 long, D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 127:1999;1696-1702
23. Cussac D., Newman-Tancredi A., Pasteau V., et al. Human dopamine D3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol. Pharmacol. 56:1999;1025-1030
24. Cussac D., Newman-Tancredi A., Audinot V., Nicholas J.P., Boutin J., Gobert A., Millan M.J. The novel dopamine receptor partial agonist, BP897, is a potent ligand at diverse adrenergic and serotonergic receptors. Abstr.-Am. Soc. Neurosci. 26:2000;1292
25. Cussac D., Newman-Tancredi A., Sezgin L., et al. [3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 361:2000;569-572
26. Cussac D., Newman-Tancredi A., Sezgin L., et al. The novel antagonist, S33084, and GR218, 231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors. Eur. J. Pharmacol. 394:2000;47-50
27. Daly S.A., Waddington J.L. Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology. 32:1993;509-510
28. de Paulis T. Sumanirole (Pharmacia). Curr. Opin. Investig. Drugs. 4:2003;77-82
29. Dubuffet T., Newman-Tancredi A., Cussac D., et al. Novel benzopyrano[3, 4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist. Bioorg. Med. Chem. Lett. 9:1999;2059-2064
30. Ekman A., Nissbrandt H., Heilig M., et al. Central administration of dopamine D3 receptor antisense to rat: effects on locomotion, dopamine release and [3H]spiperone binding. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;342-350
31. Fox S.H., Henry B., Hill M.P., et al. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan. Mov. Disord. 16:2001;642-650
32. Fox S.H., Henry B., Hill M., et al. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 17:2002;1180-1187
33. Griffon N., Pilon C., Sautel F., et al. Two intracellular pathways for the dopamine D3 receptor: opposite and synergistic interactions with cyclic AMP. J. Neurochem. 68:1997;1-9
34. Grondin R., Hadj Tahar A., Doan V.D., Ladure P., Bedard P.J. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn-Schmiedeberg's Arch. Pharmacol. 361:2000;181-186
35. Hadj Tahar A., Grondin R., Doad V.D., et al. Behavioural effects of selective dopamine D3 receptor agonists/antagonist in primate model of Parkinson's disease. Abstr.-Soc. Neurosci. 25:1999;1598
36. Hall H., Halldin C., Dijkstra D., et al. Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907. Psychopharmacology (Berl.). 128:1996;240-247
37. Henry B., Crossman A.R., Brotchie J.M. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. Adv. Neurol. 78:1998;53-61
38. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 155:1999;204-220
39. Henry B., Fox S.H., Peggs D., et al. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 14:1999;744-753
40. Henry B., Fox S.H., Crossman A.R., et al. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the mptp-lesioned primate model of Parkinson's disease. Exp. Neurol. 171:2001;139-146
41. Herroelen L., De Backer J.P., Wilczak N., et al. Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N, N-di-n-propyl-2-aminotetralin. Brain Res. 648:1994;222-228
42. Hurley M.J., Jolkkonen J., Stubbs C.M., et al. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res. 709:1996;259-264
43. Hurley M.J., Stubbs C.M., Jenner P., et al. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci. Lett. 214:1996;75-78
44. Joyce J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90:2001;231-259
45. Joyce J.N., Presgraves S.P., Borwege S., Millan M.J. D3 receptors contribute to the neuroprotective properties of D3/D2 agonists against MPP-induced neurotoxicity but not DA-induced toxicity in SH-SY5Y cells. Mov. Disord. 17(Suppl. 5):2002;10. (S19)
46. Joyce J.N., Ryoo H.L., Beach T.B., et al. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res. 955:2002;138-152
47. Khroyan T.V., Baker D.A., Neisewander J.L. Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology (Berl.). 122:1995;351-357
48. Landwehrmeyer B., Mengod G., Palacios J.M. Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res. Mol. Brain Res. 18:1993;187-192
49. Levesque D., Diaz J., Pilon C., et al. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N, N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. U. S. A. 89:1992;8155-8159
50. Ling Z.D., Rose H.C., Tong C.W., Carvey P.M. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J. Pharmacol. Exp. Ther. 289:1999;202-210
51. Maratos E.C., Jackson M.J., Pearce R.K., Jenner P. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus). Mov. Disord. 16:2000;631-641
52. Maratos E.C., Jackson M.J., Pearce R.K., et al. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp. Neurol. 179:2003;90-102
53. Mattingly B.A., Green T., Bardo M.T., et al. Paradoxical effects of dopamine D3 receptor antagonist U99194A on locomotor activity and dopamine synthesis. Abstr.-Soc. Neurosci. 27:2001;. (220.12)
54. Metman L.V., Del Dotto P., LePoole K., et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol. 56:1999;1383-1386
55. Millan M.J., Dekeyne A., Rivet J.M., et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: II. Functional and behavioral profile compared with GR218, 231 and L741, 626. J. Pharmacol. Exp. Ther. 293:2000;1063-1073
56. Millan M.J., Gobert A., Newman-Tancredi A., et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218, 231 and L741, 626. J. Pharmacol. Exp. Ther. 293:2000;1048-1062
57. Millan M.J., Dekeyne A., Chamorro S., et al. Antipsychotic profile of the novel benzopyranopyrrole and preferential dopamine D3 receptor antagonist, S33138. Eur. Neuropsychopharmacol. 12:2002;S324
58. 2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology.
59. Millan, M.J., DiCara, B., Hill, M., Jackson, M., Joyce, J., Brotchie, J., McGuire, S., Crossman, A., Jenner, P., Gobert, A., Peglion, J-L., Broco, M. in pressb. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors II: actions in rodent, primate and cellular models of anti-parkinsonian activity in comparisons to ropinirole. J. Pharmacol. Exp. Therapeut.
60. Morissette M., Goulet M., Grondin R., et al. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 10:1998;2565-2573
61. Murray A.M., Ryoo H.L., Gurevich E., et al. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U. S. A. 91:1994;11271-11275
62. Nash J.E., Fox S.H., Henry B., et al. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 165:2000;136-142
63. Nutt J.G., Carter J.H., Lea E.S., Sexton G.J. Evolution of the response to levodopa during the first 4 years of therapy. Ann. Neurol. 51:2002;686-693
64. Oh J.D., Russell D.S., Vaughan C.L., et al. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res. 813:1998;150-159
65. Oh J.D., Bibbiani F., Chase T.N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian model. Exp. Neurol. 177:2002;557-564
66. Parkinson Study Group Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA. 284:2000;1931-1938
67. Pearce R.K., Jackson M., Smith L., et al. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine- treated common marmoset (Callithix jacchus). Mov. Disord. 10:1995;731-740
68. Pearce R.K., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov. Disord. 13:1998;234-241
69. Pearce R.K., Jackson M., Britton D.R., et al. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Psychopharmacology (Berl.). 142:1999;51-60
70. Perachon S., Schwartz J.C., Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. Eur. J. Pharmacol. 366:1999;293-300
71. Piercey M.F., Moon M.W., Sethy V.H., Schreur J.K.D., Smith M.W., Tang A.H., VonVOigtlander P.F. Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype. Eur. J. Pharmacol. 317:1996;29-38
72. Pilla M., Perachon S., Sautel F., et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature. 400:1999;371-375
73. Quik M., Police S., He L., et al. Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience. 98:2000;263-273
74. Rascol O. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease? J. Neural Transm., Suppl. 55:1999;33-45
75. Rascol O., Brooks D.J., Korczyn A.D., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. New England Journal of Medicine. 342:2000;1484-1491
76. Rascol O., Arnulf I., Peyro-Saint Paul H., Brefel-Courbon C., Vidailhet M., Thalamas C., Bonnet A.M., Descombes S., Bejjani B., Fabre N., Montastruc J.L., Agid Y. Mov. Disord. 16:2001;708-713
77. Ravenscroft P., Chalon S., Brotchie J.M., Crossman A.R. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp. Neurol. 185:2004;36-46
78. Ridray S., Griffon N., Mignon V., et al. Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions. Eur. J. Neurosci. 10:1998;1676-1686
79. Robinson S.W., Caron M.G. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol. Pharmacol. 52:1997;508-514
80. Ryoo H.L, Pierrotti D., Joyce J.N. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13:1998;788-797
81. Sautel F., Griffon N., Sokoloff P., et al. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 275:1995;1239-1246
82. Savola J.M., Hill M., Engstrom M., Merivuori H., Wurster S., McGuire S.G., Fox S.H., Crossman A.R., Brotchie J.M. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 18:2003;872-883
83. Seeman P., Van Tol H.H. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15:1994;264-270
84. Shafer R.A., Levant B. The D3 dopamine receptor in cellular and organismal function. Psychopharmacology. 135:1998;1-16
85. Sokoloff P., Giros B., Martres M.P., et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151
86. Suzuki M., Hurd Y.L., Sokoloff P., et al. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res. 779:1998;58-74
87. Tel B.C., Zeng B.Y., Cannizzaro C., et al. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience. 115:2002;1047-1058
88. Van Kampen J.M., Stoessl A. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitisation to levodopa. Neuroscience. 116:2003;307-314
89. Waddington J.L., Clifford J.J., McNamara F.N., et al. The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout'). Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 25:2001;925-964